Form S-3 Amylyx Pharmaceuticals,
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Eric Dane reveals ALS diagnosis: What to know about the rare disease [USA TODAY]USA TODAY
- Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral SclerosisBusiness Wire
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock.MarketBeat
- Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire
AMLX
Earnings
- 3/4/25 - Miss
AMLX
Sec Filings
- 4/2/25 - Form 4
- 4/2/25 - Form 4
- 4/2/25 - Form 4
- AMLX's page on the SEC website